Gapping down:
In reaction to disappointing earnings/guidance:
- UA -15%, SONC -13.0%, NLSN -7.4%, EAT -6.3%, PII -6.3.%. WHR -6.1%, JBLU -3.7%, CAT -2.5%, NVS -2.3%, WAT-1.7%, LLY -1.5%, MMM -1.3%.
Other news:
- DPRX -85.5% (announces that the OneStep-1 and OneStep-2 Phase 3 clinical trials of Locilex in patients with mild infections of diabetic foot ulcers did not meet the primary clinical endpoint standardized wound care),
- FCEL -16.2% (discloses its Beacon Falls Energy Park project was not selected for contract negotiations under the The New England Clean Energy Request for Proposals),
- PLG -10.5% (will raise $40 mln through bought deal financing of 22,230,000 common shares at $1.80/share),
- MTL -10.4% (following Monday's 35% move higher),
- BPL -5.2% (priced upsized offering of 7.75 mln limited partnership units (from 7.5 mln) at $66.05 per LP Unit),
- LULU -3.2% (moving lower on UA comments),
- CRZO -2.0% (prices upsized underwritten public offering of 6 mln shares (from 5 mln) of its common stock for total gross proceeds of approximately $225 mln),
- NKE -1.7% (moving lower on UA comments),
- SKX -1.3% (moving lower on UA comments).
Analyst comments:
- CALA -20.3% (initiated with a Sell at Citigroup),
- SPN -8.4% (downgraded to Neutral from Buy at Citigroup),
- CLVS -7.7% (initiated with a Sell at Chardan Capital Markets; tgt $15),
- VFC -1.5% (downgraded to Hold from Buy at Deutsche Bank, downgraded to Neutral from Buy at Citigroup, VFC target lowered to $68 at Telsey Advisory Group following yesterday morning's Q3 earnings).